Are "Bath Salts" the next generation of stimulant abuse?

Journal of Substance Abuse Treatment

Volumn 44, Issue 1, 2013, Pages 42-45

  Winder, Gerald Scott ^a   Stern, Nathan ^b   Hosanagar, Avinash ^a,c  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

Author keywords

Addiction; Bath salts; Generation; MDPV; Mephedrone; Plant fertilizer; Stimulant; Treatment

Indexed keywords

3,4 METHYLENEDIOXYPYROVALERONE; 4' METHYLMETHCATHINONE; ANTIDEPRESSANT AGENT; BATH SALT; CENTRAL STIMULANT AGENT; LORAZEPAM; QUETIAPINE; UNCLASSIFIED DRUG;

ADULT; AGITATION; ANXIETY DISORDER; ARTICLE; AUDITORY HALLUCINATION; AWARENESS; CASE REPORT; DEPRESSION; DIAPHORESIS; DRUG DEPENDENCE; DRUG WITHDRAWAL; DYSPHORIA; EUPHORIA; HUMAN; HYPERTHERMIA; MALE; METHAMPHETAMINE DEPENDENCE; OPIATE ADDICTION; PARANOIA; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SOCIAL LIFE; TACHYCARDIA; TREMOR; VISUAL HALLUCINATION; WITHDRAWAL SYNDROME;

ADULT; BENZODIOXOLES; CENTRAL NERVOUS SYSTEM STIMULANTS; DESIGNER DRUGS; EUROPE; HUMANS; MALE; METHAMPHETAMINE; PYRROLIDINES; STREET DRUGS; SUBSTANCE ABUSE DETECTION; SUBSTANCE-RELATED DISORDERS; UNITED STATES;

EID: 84870253793     PISSN: 07405472     EISSN: 18736483     Source Type: Journal    
DOI: 10.1016/j.jsat.2012.02.003     Document Type: Article

References (20)

1. Ali W.M., Zubaid M., Al-Motarreb A., Singh R., Al-Shereiqi S.Z., Shehab A., et al. Association of khat chewing with increased risk of stroke and death in patients presenting with acute coronary syndrome. Mayo Clinic Proceedings 2010, 85(11):974-980. 10.4065/mcp.2010.0398.
2. American Association of Poison Control Centers. U.S. poison centers raise alarm about toxic substance marketed as bath salts; states begin taking action. Alexandria, VA: American Association of Poison Control Centers; March 22, 2011. Available at http://www.aapcc.org/dnn/portals/0/prrel/bathsaltsmarch22.pdf.
3. Antonowicz J.L., Metzger A.K., Ramanujam S.L. Paranoid psychosis induced by consumption of methylenedioxypyrovalerone: Two cases. General Hospital Psychiatry. 2011, 10.1016/j.genhosppsych.2011.04.010.
4. Bajaj N., Mullen D., Wylie S. Dependence and psychosis with 4-methylmethcathinone (mephedrone) use. BMJ Case Reports 2010, 2010. 10.1136/bcr.02.2010.2780.
5. Brandt S.D., Freeman S., Sumnall H.R., Measham F., Cole J. Analysis of NRG "legal highs" in the UK: Identification and formation of novel cathinones. Drug Testing and Analysis. 2010, 10.1002/dta.204.
6. CDC Emergency Department Visits After Use of a Drug Sold as "Bath Salts" - Michigan, November 13, 2010-March 31, 2011. MMWR 2011, 60(19):624-627.
7. Coppola M., Mondola R. 3,4-Methylenedioxypyrovalerone (MDPV): Chemistry, pharmacology and toxicology of a new designer drug of abuse marketed online. Toxicology Letters 2011, 10.1016/j.toxlet.2011.10.002.
8. Dargan P.I., Sedefov R., Gallegos A., Wood D.M. The pharmacology and toxicology of the synthetic cathinone mephedrone (4-methylmethcathinone). Drug Testing and Analysis 2011, 3(7-8):454-463. 10.1002/dta.312.
9. Drug Enforcement administration. DEA Moves to Emergency Control Synthetic Stimulants; Agency Will Study Whether To Permanently Control Three Substances. Drug Enforcement administration September 7 2011. Available at http://www.justice.gov/dea/pubs/pressrel/pr090711.html.
10. Hill S.L., Thomas S.H.L. Clinical toxicology of newer recreational drugs. Clinical Toxicology (Philadelphia, Pa.) 2011, 49(8):705-719. 10.3109/15563650.2011.615318.
11. Jankovics P., Váradi A., Tölgyesi L., Lohner S., Németh-Palotás J., Koszegi-Szalai H. Identification and characterization of the new designer drug 4'-methylethcathinone (4-MEC) and elaboration of a novel liquid chromatography-tandem mass spectrometry (LC-MS/MS) screening method for seven different methcathinone analogs. Forensic Science International 2011, 210(1-3):213-220. 10.1016/j.forsciint.2011.03.019.
12. Kriikku P., Wilhelm L., Schwarz O., Rintatalo J. New designer drug of abuse: 3,4-Methylenedioxypyrovalerone (MDPV). Findings from apprehended drivers in Finland. Forensic Science International 2011, 210(1-3):195-200. 10.1016/j.forsciint.2011.03.015.
13. Meltzer P.C., Butler D., Deschamps J.R., Madras B.K. 1-(4-methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (pyrovalerone) analogues: A promising class of monoamine uptake inhibitors. Journal of Medicinal Chemistry 2006, 49(4):1420-1432. 10.1021/jm050797a.
14. Morris K. UK places generic ban on mephedrone drug family. Lancet 2010, 375(9723):1333-1334.
15. Nicholson P.J., Quinn M.J., Dodd J.D. Headshop heartache: Acute mephedrone "meow" myocarditis. Heart (British Cardiac Society) 2010, 96(24):2051-2052. 10.1136/hrt.2010.209338.
16. Psychonaut Webmapping Research Group Mephedrone report 2009, Institute of Psychiatry, King's College London, London, UK.
17. Schifano F., Albanese A., Fergus S., Stair J.L., Deluca P., Corazza O., et al. Mephedrone (4-methylmethcathinone; "meow meow"): Chemical, pharmacological and clinical issues. Psychopharmacology 2011, 214(3):593-602. 10.1007/s00213-010-2070-x.
18. Spiller H.A., Ryan M.L., Weston R.G., Jansen J. Clinical experience with and analytical confirmation of "bath salts" and "legal highs" (synthetic cathinones) in the United States. Clinical Toxicology (Philadelphia, Pa.) 2011, 49(6):499-505. 10.3109/15563650.2011.590812.
19. Winstock A., Mitcheson L., Ramsey J., Davies S., Puchnarewicz M., Marsden J. Mephedrone: Use, subjective effects and health risks. Addiction (Abingdon, England) 2011, 106(11):1991-1996. 10.1111/j.1360-0443.2011.03502.x.
20. Wood D.M., Davies S., Puchnarewicz M., Button J., Archer R., Ovaska H., et al. Recreational use of mephedrone (4-methylmethcathinone, 4-MMC) with associated sympathomimetic toxicity. Journal of Medical Toxicology: Official Journal of the American College of Medical Toxicology 2010, 6(3):327-330. 10.1007/s13181-010-0018-5.